Free Trial
NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

NextCure logo
$6.06 +0.07 (+1.08%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About NextCure Stock (NASDAQ:NXTC)

Advanced

Key Stats

Today's Range
$5.82
$6.13
50-Day Range
$4.80
$6.00
52-Week Range
$2.69
$19.20
Volume
3,533 shs
Average Volume
46,756 shs
Market Capitalization
$16.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50
Consensus Rating
Hold

Company Overview

NextCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

NXTC MarketRank™: 

NextCure scored higher than 85% of companies evaluated by MarketBeat, and ranked 133rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NextCure has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    NextCure has a consensus price target of $25.50, representing about 320.4% upside from its current price of $6.07.

  • Amount of Analyst Coverage

    NextCure has only been the subject of 2 research reports in the past 90 days.

  • Read more about NextCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NextCure is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NextCure is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NextCure has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NextCure's valuation and earnings.
  • Percentage of Shares Shorted

    2.17% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 20.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NextCure does not currently pay a dividend.

  • Dividend Growth

    NextCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.17% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 20.91%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    1 people have added NextCure to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NextCure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NextCure's insider trading history.
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NXTC Stock News Headlines

Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
NextCure (NXTC) Q2 Loss Widens 71%
See More Headlines

NXTC Stock Analysis - Frequently Asked Questions

NextCure's stock was trading at $9.2520 at the beginning of the year. Since then, NXTC stock has decreased by 34.4% and is now trading at $6.0650.

NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($11.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.62) by $6.67.

NextCure's stock reverse split on the morning of Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/07/2025
Today
10/07/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NXTC
CIK
1661059
Fax
N/A
Employees
90
Year Founded
2015

Price Target and Rating

High Price Target
$36.00
Low Price Target
$15.00
Potential Upside/Downside
+325.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($25.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.62%
Return on Assets
-85.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.71
Quick Ratio
3.71

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$28.06 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
2,676,000
Free Float
2,320,000
Market Cap
$16.04 million
Optionable
Optionable
Beta
1.34

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:NXTC) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners